Cerus Corporation (NASDAQ:CERS) developer of biomedical products, is reporting second quarter earnings results on Tuesday 4th August 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.11 per share.
For the full year, analysts predict revenues of $ 112.80 million, while looking forward to loss of $ 0.42 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 89.00 million ~ $ 93.00 million
Click Here For More Historical Outlooks Of Cerus Corporation
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Cerus Corporation
Stock Performance
According to the previous trading day, closing price of CERS was $ 7.41, representing a 173.43 % increase from the 52 week low of $ 2.71 and a 1.07 % decrease over the 52 week high of $ 7.49.
The company has a market capital of $ 1.22 billion and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CERS” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Cerus Corporation will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cerus.com
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.
